Key clinical point: Initial response to induction therapy with novel agents prepares patients for favorable outcomes after stem cell transplant.
Major finding: Triplet induction beat doublet with regards to early response (95.4% vs. 84.02% [doublets], P < .003), stem cell mobilization (88.6% vs. 76.8%, P < .005) and lower day-100 transplant-related mortality (P < .001).
Study details: An analysis of 326 multiple myeloma patients who received novel agents based induction prior to autologous stem cell transplant.
Disclosures: The authors declared that they had no conflicts of interest.
Kumar L et al. Clin Lymphoma Myeloma Leuk. 2020 Sep 18. doi: 10.1016/j.clml.2020.08.021.